The research study consists of the participant agreeing to 1) the use of preoperative molecular testing (ThyroSeq) to guide extent of initial surgery and 2) the prospective collection of medical record data related to treatment of thyroid cancer.
The aim of the proposed pilot study is to use a clinical algorithm that incorporates molecular, clinical and radiographic factors to inform surgical management. This study is the first to propose molecular-directed surgical management for this commonly diagnosed cancer.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
100
Thyroid lobectomy is removal of only part of the thyroid
Total thyroidectomy with central compartment lymph node dissection is removal of the entire thyroid with the surrounding lymph nodes
University of Pittsburgh
Pittsburgh, Pennsylvania, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Number of patients who require completion thyroidectomy for aggressive histology features
Histology characteristics of tumor will be assessed including type of cancer, extrathyroidal extension, lymph node metastasis, and margin status to assess if completion thyroidectomy is needed per the 2015 ATA guidelines
Time frame: 2 years
Number of patients who had central compartment neck dissection but no lymph node metastasis were identified
Time frame: 2 years
Number of patients with operative complications
incidence of permanent nerve injury, hypocalcemia, readmission
Time frame: 2 years
Recurrence
Time frame: >2 years
QOL metric - FACT-G cumulative score preop, postop, and at followup
Time frame: 2 years
QOL metric - QOL-Thyroid cumulative score preop, postop, and at followup
Time frame: 2 years
QOL metric - SF36 cumulative score preop, postop, and at followup
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.